DexCom, Inc. (NASDAQ:DXCM) CFO Quentin S. Blackford sold 7,149 shares of DexCom stock in a transaction on Monday, September 10th. The shares were sold at an average price of $143.76, for a total transaction of $1,027,740.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ:DXCM traded down $0.63 during midday trading on Wednesday, hitting $146.24. 1,006,200 shares of the company’s stock traded hands, compared to its average volume of 1,132,733. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $12.68 billion, a price-to-earnings ratio of -251.07 and a beta of 0.44. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $148.48.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The business had revenue of $242.50 million for the quarter, compared to analyst estimates of $205.81 million. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The business’s quarterly revenue was up 42.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.16) EPS. analysts predict that DexCom, Inc. will post -0.47 earnings per share for the current year.
Several large investors have recently bought and sold shares of DXCM. Signaturefd LLC acquired a new position in DexCom in the 1st quarter worth $105,000. Cerebellum GP LLC acquired a new position in DexCom in the 2nd quarter worth $171,000. SG Americas Securities LLC acquired a new position in DexCom in the 1st quarter worth $175,000. Clinton Group Inc. acquired a new position in DexCom in the 2nd quarter worth $201,000. Finally, Bank Pictet & Cie Asia Ltd. acquired a new position in DexCom in the 2nd quarter worth $218,000.
A number of brokerages have weighed in on DXCM. Canaccord Genuity lifted their price target on shares of DexCom from $85.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, June 28th. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Raymond James upgraded shares of DexCom from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd. Northland Securities upgraded shares of DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday. Finally, BMO Capital Markets lifted their price target on shares of DexCom to $112.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $111.64.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: Asset Allocation and Your Retirement
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.